PrecisionRx AI distills your patient's genomic, lab, medication, and wearable data into the small set of decisions that matter for today's visit. Drug-gene safety, drug-drug interactions, missed labs, cardiometabolic risk — surfaced when relevant, suppressed when not.
From $39 / clinician / mo · SaMD-track · Concept-phase prototype
A clinical decision support OS for licensed clinicians at the chart, and a specialist therapeutics studio for the teams designing N-of-1 and ultra-rare disease therapies. Separate products, separate users, separate regulatory posture — designed to interoperate at a small set of explicit hand-offs.
Decision support for licensed clinicians at the chart. Genomic, lab, medication, wearable, and EHR signals — surfaced as evidence-linked recommendations the clinician approves at every step.
Therapy candidate design + IND-track development for ultra-rare and individually-variant disease cases. ASO, CRISPR, mRNA, AAV, and protein-replacement modalities under one specialist-team workspace, with named-specialist review at every gate.
Two products · Three signed integration touchpoints · Zero shared codebase
Healthcare is moving toward precision medicine, but most clinicians don't have the time, workflow, or integrated software to use multi-modal patient data effectively. A single patient's IVD labs, pharmacogenomic findings, sequencing results, medication history, prior side effects, wearable trends, and symptoms live in disconnected systems — while the AMA describes documentation burden following physicians home, CPIC names workflow integration as the leading barrier to PGx adoption, and reviews of patient-generated data flag clinical validity and information overload.
Multi-modal patient data turned into evidence-linked therapy considerations, medication review flags, monitoring plans, and reports — clinician-reviewed at every gate.
“I don't have time to interpret all this data.”
A concise patient picture: active problems, current and prior medications, key labs, genomic findings, wearable trends, and the open therapy considerations for today's visit — surfaced in one chart instead of seven.
“PGx reports are hard to use at the point of care.”
Pharmacogenomic results connect directly to the patient's current and prior medications. Each flag shows the gene, phenotype, drug, and CPIC / PharmGKB evidence source that triggered it — not a 30-page PDF.
“Wearable data is noisy and overwhelming.”
No raw data dump. Only clinically relevant changes — sleep decline or resting heart rate increase after a medication start — framed as monitoring considerations, with wear-time confidence and stale-feed gating.
“Labs, meds, and symptoms aren't connected.”
Abnormal labs link to medication safety and disease-management context. Elevated ALT / AST triggers hepatic monitoring on relevant medications. Reduced eGFR triggers renal medication review. The connections happen automatically; the clinician approves.
“I need reports I can actually use in a visit.”
Clinician-reviewed reports summarize patient-specific factors, therapy considerations, evidence strength, monitoring needs, and patient-friendly explanations — formatted for the chart note, the patient handout, and the specialist referral.
Help clinicians practice precision medicine without adding more data burden.
Evidence-linked, audit-logged, clinician-final at every step.
Adoption can start with a single lane and expand without re-platforming. Every module routes back to the same versioned rule engine and audit-logged review surface. Six teased here — see the full nine on the Clinical OS page.
Multimodal chart that unifies meds, labs, PGx, wearables, phenotype, timeline.
CPIC- and PharmGKB-aligned phenotype calls with versioned evidence.
Lab + IVD into FHIR-ready Observation context with LOINC and quality grading.
ApoB / Lp(a) / HbA1c interpreted with statin tolerability + PGx-aware therapy review.
Sleep, HRV, resting HR, CGM correlated to medication initiation events to surface side effects early.
Co-sign, suppression, amendment, audit log, quality-override governance.
A bounded decision-support flow. Each phase is independently auditable and reversible.
Pull the data the patient already has into one FHIR-shaped chart.
Versioned deterministic rules check phenotype against meds, labs, wearables.
The 1–3 items that matter today. Longitudinal context collapses below.
Co-sign, audit, amend. The clinician approves every action.
No enterprise gating. No IT ticket required for solo and small-group onboarding. Annual or monthly billing.
Solo
$39/clinician/mo
For solo physicians, longevity practices, and concierge clinics.
Group
Most popular$79/clinician/mo
Small groups (2–25 clinicians) and cardiometabolic / psychiatry clinics.
Health system
Custom
For 25+ clinicians, integrated delivery networks, and ACOs.
PGx kit pull-through is available as a $0 entry plan with revenue share. Ask for the partnership sheet.
Jane Smith, 38F. CYP2C19 PM on sertraline. New atorvastatin + clarithromycin clash. Three things to address today, eight more in the chart for context. No demo call required.